Catalio Capital Management, LP has filed a restatement of its Form 13F-HR for the period ending December 31, 2025. The filing, submitted by Chief Compliance Officer and Head of Operations Olga Maltseva, updates the firm's portfolio holdings as of the close of the previous year.
The report lists a total of 45 distinct securities held by the firm. The portfolio is heavily weighted toward the healthcare and biotechnology sectors, featuring a mix of common stocks and sponsored American Depositary Shares (ADS).
Among the largest positions disclosed in the filing are shares of Eledon Pharmaceuticals, Inc., held in the amount of 1,259,820 shares, and Hyperfine Inc., Class A Common Stock, held at 1,320,041 shares. Other notable biotechnology holdings include Fulcrum Therapeutics, Inc., with 201,301 shares, and Protara Therapeutics, Inc., with 1,446,254 shares.
The portfolio also includes several large-cap healthcare names, such as Boston Scientific Corporation (360,428 shares), Gilead Sciences, Inc. (289,312 shares), and Edwards Lifesciences Corporation (187,048 shares). Additionally, the filing discloses positions in companies like Intuitive Surgical, Inc., Regeneron Pharmaceuticals, and Uniqure NV.
